Palisade Bio: Undervalued Biotech With Blockbuster Potential, Initiating With A Speculative Buy Rating [Seeking Alpha]
Palisade Bio, Inc. (PALI)
Company Research
Source: Seeking Alpha
PALI-2108's phase 1 data show promising efficacy, mechanistic engagement, and improved tolerability versus systemic PDE4 inhibitors, supporting further development. PALI's $133M cash position provides 3–4 years of runway, mitigating near-term financing risk for advancing into pivotal phase 2 trials. A positive phase 2 ulcerative colitis readout could meaningfully re-rate PALI's valuation and position it as a potential acquisition target. Lock Stock/DigitalVision via Getty Images Investment thesis I am initiating Palisade Bio ( PALI ) with a speculative buy rating. In my view, Palisade Bio represents an attractive asymmetric opportunity in the inflammatory bowel disease (IBD) space, which is analogous to ABIVAX (
Show less
Read more
Impact Snapshot
Event Time:
PALI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
PALI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
PALI alerts
High impacting Palisade Bio, Inc. news events
Weekly update
A roundup of the hottest topics
PALI
News
- Palisade Bio (PALI) Reports Positive Phase 1b Data for PALI-2108 in UC Patients [Yahoo! Finance]Yahoo! Finance
- Palisade Bio Announces Participation in Two Upcoming Investor ConferencesGlobeNewswire
- Palisade Bio (PALI) is now covered by Stifel Nicolaus. They set a "buy" rating and a $5.00 price target on the stock.MarketBeat
- Palisade Bio Reports Rapid Clinical, Histologic and New Mechanistic Colon Tissue RNA Sequencing Data Supporting Targeted Activity of PALI-2108 at ECCO 2026GlobeNewswire
- Palisade Bio Appoints Global IBD Precision Medicine Leader Bram Verstockt, MD, PhD to Clinical Advisory BoardGlobeNewswire
PALI
Sec Filings
- 3/20/26 - Form 10-K
- 2/17/26 - Form SCHEDULE
- 2/17/26 - Form SCHEDULE
- PALI's page on the SEC website